Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 0.00
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 2.50M
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 -0.428M
September 30, 2024 18.32M
June 30, 2024 -7.361M
March 31, 2024 18.91M
December 31, 2023 14.52M
September 30, 2023 0.18M
June 30, 2023 -3.154M
March 31, 2023 26.24M
December 31, 2022 3.463M
September 30, 2022 4.303M
June 30, 2022 28.34M
March 31, 2022 -3.083M
December 31, 2021 -3.523M
September 30, 2021 -11.53M
June 30, 2021 -28.77M
March 31, 2021 -4.071M
December 31, 2020 -53.47M
September 30, 2020 -0.162M
Date Value
June 30, 2020 -0.258M
March 31, 2020 4.841M
December 31, 2019 1.549M
September 30, 2019 1.453M
June 30, 2019 -8.058M
March 31, 2019 0.60M
December 31, 2018 4.654M
September 30, 2018 4.679M
June 30, 2018 13.81M
March 31, 2018 -1.773M
December 31, 2017 -2.571M
September 30, 2017 4.935M
June 30, 2017 -6.012M
March 31, 2017 0.018M
December 31, 2016 14.06M
September 30, 2016 20.23M
June 30, 2016 5.127M
March 31, 2016 -9.291M
December 31, 2015 15.66M
September 30, 2015 2.765M
June 30, 2015 15.73M
March 31, 2015 -40.58M
December 31, 2014 5.254M
September 30, 2014 0.676M
June 30, 2014 6.902M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.147M
Agenus, Inc. -19.88M
Amgen, Inc. -649.00M
Anika Therapeutics, Inc. -1.756M
BioCryst Pharmaceuticals, Inc. -78.88M